Austin-based Phantom Neuro has closed an oversubscribed $19 million Series A funding round led by Ottobock, the German prosthetics and orthotics leader. The round brings Phantom''s total funding to $28 million and will support preclinical and first-in-human trials of Phantom X, a minimally invasive neural interface designed to give amputees lifelike prosthetic control.
How Phantom X works
Phantom X is implanted just beneath the skin in an outpatient procedure, where it reads electrical activity from residual muscles and translates intent into precise digital commands for prosthetic limbs and robotic devices. The platform recently received FDA Breakthrough Device and Targeted Acceleration Pathway (TAP) designations, both of which can shorten the regulatory runway to commercial use.
A strategic check from Ottobock
Ottobock''s lead investment is strategic: the 100-year-old prosthetics firm is rapidly expanding into AI-driven neural interfaces, where startups including Science Corporation and Synchron are racing to commercialise next-generation BCI technology. Other Series A backers include Breakout Ventures, Draper Associates, LionBird, Time BioVentures and Brown Advisory.
Trials and beyond
Funding will support preclinical testing, first-in-human studies, regulatory submissions and expanded R&D for control applications beyond prosthetics – including robotic surgery and assistive devices. Phantom is also collaborating on muscle-signal decoding research with academic partners in Texas and Europe.
Why it matters
The Phantom Neuro raise reinforces a wave of capital flowing into neural interfaces and AI-controlled medical devices in 2026, alongside Microsure''s MUSA-3 CE Mark and Aidoc''s expanded FDA clearances. With BCI players competing for clinical milestones, integrated prosthetic ecosystems may emerge as a viable middle path between fully implanted brain devices and surface EMG controls.
Reporting based on coverage from MassDevice, BioSpace and PR Newswire.